Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Vertex Trial on Hold

<< Previous

Bullboard Posts

Next >>

Comment by BioTeckon May 02, 2022 2:06pm

156 Views

Post# 34648343

RE:RE:RE:RE:Vertex Trial on Hold

Don't forget the ipsc tech needs to be acquired AND proven. The conformal coating needs to be proven. A billion in the hand is worth 2 in the bush. Not saying it's impossible but it will take many years to prove out and by then things can change drastically. I'd happily sell my shares for a 1 bil offer. .

steadfast wrote:
Bio-Teck, I believe SVA is worth far more than $1B. Once SVA secure and advance
iPSC Stem Cell Technology and the Conformal Coating SVA should be worth $2B
which equals $6.80 per share. This is not including Thyroid & Hemo.
Phil reported at AGM SVA wants to treat millions of patients world-wide, he met with insce
co willing to pay $100,000 to $200,000 range per course of treatment per patient and
he added times 2 = $200,000 to $400,000.